The Middlemen Running Your Medicine: How Pharmacy Benefit Managers Decide What You Can and Cannot Afford

When a physician writes a prescription, most patients assume the path forward is straightforward: visit the pharmacy, present insurance, receive medication. What that mental model leaves out is a powerful third party operating almost entirely out of public view. Pharmacy Benefit Managers, commonly referred to as PBMs, sit between your insurance plan and your pharmacist, and the decisions they make on a daily basis shape medication access for hundreds of millions of Americans.

Three companies — CVS Caremark, Express Scripts, and OptumRx — collectively manage pharmacy benefits for roughly 80 percent of insured Americans, according to the Federal Trade Commission. That concentration of influence carries consequences that patients are rarely warned about.

What a Pharmacy Benefit Manager Actually Does

On paper, PBMs exist to administer prescription drug benefits on behalf of health insurers, employers, and government programs like Medicare Part D. Their stated purpose is to negotiate lower drug prices with manufacturers and streamline pharmacy reimbursement. In practice, their role is considerably more complex — and considerably more profitable.

PBMs construct and maintain formularies, which are the tiered lists of covered medications that determine how much a patient pays out of pocket. A drug on Tier 1 might cost a patient ten dollars; the same therapeutic class of drug placed on Tier 3 or Tier 4 might cost several hundred. The PBM decides which tier each medication occupies, and that decision is not purely clinical.

Manufacturers pay PBMs rebates — essentially retroactive discounts — in exchange for favorable formulary placement. The critical problem is that these rebates are calculated based on a drug's list price, not its net cost. This creates a perverse incentive: PBMs may prefer a higher-list-price drug that generates a large rebate over a lower-list-price drug that is genuinely more affordable for the patient. The rebate flows to the PBM and, to varying degrees, to the insurer. The patient standing at the pharmacy counter sees none of it.

Formulary Restrictions and the Step Therapy Trap

One of the most consequential tools in a PBM's arsenal is step therapy, sometimes called "fail first" protocols. Under this approach, a plan will not cover a physician-prescribed medication until the patient has tried and demonstrably failed on one or more cheaper alternatives — alternatives that often generate more favorable economics for the PBM.

Consider a patient with rheumatoid arthritis whose specialist prescribes a specific biologic medication based on the patient's unique history, comorbidities, and prior treatment experience. The PBM's formulary may require that patient to cycle through two or three other biologics first, spending months on treatments their physician did not recommend, before the plan will authorize coverage. During that period, the patient may experience inadequate disease control, additional office visits, and potential joint damage that might have been prevented.

Step therapy is not inherently unreasonable — cost-conscious prescribing has a legitimate place in healthcare — but the criteria that trigger these requirements are set by PBMs with limited clinical oversight and significant financial motivation.

The Spread Pricing Problem

Another mechanism deserves particular attention. Spread pricing occurs when a PBM charges an insurer more for a drug than it actually reimburses the dispensing pharmacy, pocketing the difference. A 2019 Ohio Medicaid audit revealed that PBMs had collected more than $224 million in spread pricing over a single year on generic drugs alone. Patients enrolled in those plans were not receiving the benefit of lower generic costs — those savings were captured upstream.

This practice disproportionately affects patients in Medicaid managed care and employer-sponsored plans where oversight is limited. The spread is invisible to the plan's members and, frequently, to the plan administrators themselves.

Preferred Pharmacy Networks and Geographic Barriers

PBMs also designate preferred pharmacy networks — chains or mail-order services that offer lower copays in exchange for higher dispensing volumes. Patients who use pharmacies outside these networks face substantially higher cost-sharing, even if a local independent pharmacy is their only convenient option. In rural communities, where independent pharmacies often serve as the sole accessible provider, preferred network exclusions can effectively price patients out of their medications.

Mail-order mandates present a related challenge. Some PBM-administered plans require that maintenance medications — those taken long-term for chronic conditions — be filled through a PBM-owned mail-order pharmacy rather than a local retail location. When a PBM owns both the benefit manager function and the mail-order pharmacy, the financial conflicts of interest multiply.

Regulatory Pressure and What May Be Changing

The Federal Trade Commission launched a formal investigation into PBM practices in 2022, and its interim report, released in 2024, documented how the largest PBMs have used their market position to disadvantage independent pharmacies and steer patients toward affiliated dispensing operations. Bipartisan legislation targeting PBM transparency has advanced in both the House and Senate, though comprehensive reform has not yet been enacted.

Some states have moved independently. Arkansas, for instance, enacted legislation limiting spread pricing in Medicaid. Other states have passed transparency requirements compelling PBMs to disclose rebate arrangements. The patchwork nature of state-level reform, however, means patient protections vary dramatically depending on geography.

The Inflation Reduction Act of 2022 introduced rebate rule reforms for Medicare Part D, requiring that a greater share of manufacturer rebates be applied at the point of sale, reducing out-of-pocket costs for beneficiaries. Analysts consider this a meaningful step, though its scope is limited to the Medicare population.

What Patients Can Do Right Now

Understanding the system is the first form of advocacy available to patients. Several practical steps can help:

Request a formulary exception. If your physician believes a non-preferred drug is medically necessary, a formal exception request — supported by clinical documentation — can sometimes override standard formulary restrictions. Your physician's office can initiate this process.

Ask about step therapy override laws. Many states now require health plans to grant step therapy overrides under specific circumstances, such as when a patient has already failed the required alternatives or when the required drug poses a documented safety risk. Your state insurance commissioner's website is a starting point for understanding your rights.

Compare cash prices against your copay. Tools such as GoodRx and pharmacy discount programs occasionally offer lower prices than your insurance copay, particularly for generic medications. This counterintuitive reality is a direct consequence of how PBM reimbursement structures are designed.

Engage your pharmacist. Licensed pharmacists are often familiar with formulary alternatives and can communicate with your prescriber about therapeutically equivalent options that may be covered at a lower tier.

The Transparency Gap

Perhaps the most significant problem with the current PBM model is not any single practice but the systemic opacity that allows these practices to persist. Patients cannot easily learn why a specific drug was excluded from their formulary, how rebate dollars were allocated, or what financial relationship exists between their insurer and the company managing their drug benefits. Meaningful reform will require not only legislative action but a cultural shift toward treating prescription drug pricing as a matter of public health transparency rather than proprietary business information.

For patients managing chronic conditions, rare diseases, or complex medication regimens, the stakes of this opacity are not abstract. They are measured in delayed treatments, abandoned prescriptions, and health outcomes that fall short of what modern medicine is capable of delivering. Knowing who holds the keys to your medication access is the first step toward demanding those keys be used differently.